Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 4/2014

01.08.2014 | Therapy in Practice

A Practical Approach to Cutaneous Sarcoidosis

verfasst von: Karolyn A. Wanat, Misha Rosenbach

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Sarcoidosis is a chronic inflammatory disorder that has the potential to affect multiple organs, including the skin. Its cutaneous manifestations are varied and can provide clues to underlying systemic manifestations. Unfortunately, they also can be disfiguring. Therapy is usually directed at the organ system most severely affected, which often may help cutaneous disease. However, cutaneous disease may be recalcitrant to treatment directed at extracutaneous disease, or it may be severe enough to require targeted therapy. This article focuses on the dermatologist’s role in recognizing and diagnosing cutaneous sarcoidosis, evaluating patients for systemic disease involvement, and treating the skin manifestations of sarcoidosis.
Literatur
1.
III Italian Conference on Sarcoidosis and Other Granulomatous Disorders. Padua, April 12–13, 1991. Proceedings and abstracts. Sarcoidosis. 1991;8(2):161–202.
2.
Proceedings of the 1991 XIIth World Congress on Sarcoidosis. Kyoto, Japan, September 8–13, 1991. Sarcoidosis. 1992;9 Suppl 1:1–683.
3.
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–55.
4.
Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35.PubMed
5.
Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect. 1998;13(3):166–73.PubMed
6.
Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41.PubMed
7.
Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, et al. Epidemiology of sarcoidosis in Japan. Eur Respiratory J. 2008;31(2):372–9.
8.
Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699 e1–18; quiz 717–8.
9.
Noor A, Knox KS. Immunopathogenesis of sarcoidosis. Clin Dermatol. 2007;25(3):250–8.
10.
Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.PubMed
11.
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. New Engl J Med. 2007;357(21):2153–65.PubMed
12.
Chen ES, Moller DR. Sarcoidosis—scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7(8):457–67.PubMed
13.
Rossman MD, Thompson B, Frederick M, Iannuzzi MC, Rybicki BA, Pander JP, et al. HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):125–32.PubMed
14.
Iannuzzi MC, Iyengar SK, Gray-McGuire C, Elston RC, Baughman RP, Donohue JF, et al. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun. 2005;6(6):509–18.PubMed
15.
Hofmann S, Fischer A, Nothnagel M, Jacobs G, Schmid B, Wittig M, et al. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. Eur Respir J. 2013;41(4):888–900.PubMed
16.
Spagnolo P, Schwartz DA. Genetic predisposition to sarcoidosis: another brick in the wall. Eur Respir J. 2013;41(4):778–80.PubMed
17.
Franke A, Fischer A, Nothnagel M, Becker C, Grabe N, Till A, et al. Genome-wide association analysis in sarcoidosis and Crohn’s disease unravels a common susceptibility locus on 10p12.2. Gastroenterology. 2008;135(4):1207–15.PubMed
18.
Newman KL, Newman LS. Occupational causes of sarcoidosis. Curr Opin Allergy Clin Immunol. 2012;12(2):145–50.PubMed
19.
Reich JM. Sarcoidosis and World Trade Center disaster. J Occup Environ Med. 2012;54(1):2; author reply -3.
20.
Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J. 2007;30(3):508–16.PubMed
21.
Rutherford RM, Gilmartin JJ. Mycobacteria in pathogenesis of sarcoidosis. Chest. 2004;125(1):354.PubMed
22.
Brownell I, Ramirez-Valle F, Sanchez M, Prystowsky S. Evidence for mycobacteria in sarcoidosis. Am J Respir Cell Mol Biol. 2011;45(5):899–905.PubMedCentralPubMed
23.
Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol. 2012;32(5):1129–40.PubMedCentralPubMed
24.
Furusawa H, Suzuki Y, Miyazaki Y, Inase N, Eishi Y. Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respir Investig. 2012;50(3):104–9.PubMed
25.
Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–73.PubMedCentralPubMed
26.
Parisinos CA. Sarcoidosis is a Th1/Th17 multisystem disorder: wider implications. Thorax. 2011;66(11):1011–2; author reply 1012.
27.
Zissel G, Prasse A, Muller-Quernheim J. Sarcoidosis—immunopathogenetic concepts. Semin Respir Crit Care Med. 2007;28(1):3–14.PubMed
28.
Zissel G, Prasse A, Muller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):390–403.PubMed
29.
Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66(2):144–50.PubMed
30.
Huang H, Lu Z, Jiang C, Liu J, Wang Y, Xu Z. Imbalance between Th17 and regulatory T-Cells in sarcoidosis. Int J Mol Sci. 2013;14(11):21463–73.PubMedCentralPubMed
31.
Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology. 2012;51(1):37–46.PubMed
32.
Urbankowski T, Hoser G, Domagala-Kulawik J. Th1/Th2/Th17 related cytokines in the bronchoalveolar lavage fluid of patients with sarcoidosis: association with smoking. Pol Arch Med Wewn. 2012;122(7–8):320–5.PubMed
33.
Kim HS, Choi D, Lim LL, Allada G, Smith JR, Austin CR, et al. Association of interleukin 23 receptor gene with sarcoidosis. Dis Markers. 2011;31(1):17–24.PubMedCentralPubMed
34.
Schurmann M, Kwiatkowski R, Albrecht M, Fischer A, Hampe J, Muller-Quernheim J, et al. Study of Toll-like receptor gene loci in sarcoidosis. Clin Exp Immunol. 2008;152(3):423–31.PubMedCentralPubMed
35.
Veltkamp M, Van Moorsel CH, Rijkers GT, Ruven HJ, Van Den Bosch JM, Grutters JC. Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin Exp Immunol. 2010;162(1):68–74.PubMedCentralPubMed
36.
Richmond BW, Drake WP. Vitamin D innate immunity, and sarcoidosis granulomatous inflammation: insights from mycobacterial research. Curr Opin Pulm Med. 2010;16(5):461–4.PubMed
37.
Gazouli M, Koundourakis A, Ikonomopoulos J, Gialafos EJ, Rapti A, Gorgoulis VG, et al. CARD15/NOD2, CD14, and Toll-like receptor 4 gene polymorphisms in Greek patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(1):23–9.PubMed
38.
Marinis JM, Homer CR, McDonald C, Abbott DW. A novel motif in the Crohn’s disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J Biol Chem. 2011;286(3):1938–50.PubMedCentralPubMed
39.
Culver DA, Newman LS, Kavuru MS. Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol. 2007;25(3):267–75.
40.
Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part II. Extracutaneous disease. J Am Acad Dermatol. 2012;66(5):719 e1–10; quiz 729–30.
41.
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–9.PubMed
42.
Nozaki K, Judson MA. Neurosarcoidosis: clinical manifestations, diagnosis and treatment. Presse Med. 2012;41(6 Pt 2):e331–48.PubMed
43.
Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist’s perspective. Am J Kidney Dis. 2006;48(5):856–70.PubMed
44.
Mantini N, Williams B Jr, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: a clinician’s review on how to approach the patient with cardiac sarcoid. Clin Cardiol. 2012;35(7):410–5.PubMed
45.
Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.PubMed
46.
English JC 3rd, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol. 2001;44(5):725–43; quiz 744–6.
47.
Newman LS, Rose CS, Maier LA. Sarcoidosis. New Engl J Med. 1997;336(17):1224–34.PubMed
48.
49.
Marchell RM, Judson MA. Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):442–51.PubMed
50.
Marchell RM, Judson MA. Chronic cutaneous lesions of sarcoidosis. Clin Dermatol. 2007;25(3):295–302.
51.
Mana J, Marcoval J. Skin manifestations of sarcoidosis. Presse Med. 2012;41(6 Pt 2):e355–74.PubMed
52.
Marcoval J, Mana J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol. 2011;36(7):739–44.PubMed
53.
Higgins EM, Salisbury JR, Du Vivier AW. Subcutaneous sarcoidosis. Clin Exp Dermatol. 1993;18(1):65–6.PubMed
54.
Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease? J Am Acad Dermatol. 2006;54(1):55–60.PubMed
55.
El Sayed F, Dhaybi R, Ammoury A. Subcutaneous nodular sarcoidosis and systemic involvement successfully treated with doxycycline. Leban Med J. 2006;54(1):42–4.
56.
Marcoval J, Moreno A, Mana J, Peyri J. Subcutaneous sarcoidosis. Dermatol Clin. 2008;26(4):553–6, ix.
57.
Dalle Vedove C, Colato C, Girolomoni G. Subcutaneous sarcoidosis: report of two cases and review of the literature. Clin Rheumatol. 2011;30(8):1123–8.
58.
Meyer-Gonzalez T, Suarez-Perez JA, Lopez-Navarro N, Hidalgo A, Herrera-Ceballos E. Subcutaneous sarcoidosis: a predictor of systemic disease? Eur J Intern Med. 2011;22(6):e162–3.PubMed
59.
Yanardag H, Pamuk ON, Pamuk GE. Lupus pernio in sarcoidosis: clinical features and treatment outcomes of 14 patients. J Clin Rheumatol. 2003;9(2):72–6.PubMed
60.
Spiteri MA, Matthey F, Gordon T, Carstairs LS, James DG. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol. 1985;112(3):315–22.PubMed
61.
Elgart ML. Cutaneous sarcoidosis: definitions and types of lesions. Clin Dermatol. 1986;4(4):35–45.
62.
Elgart ML. Cutaneous lesions of sarcoidosis. Prim Care. 1978;5(2):249–62.PubMed
63.
Efthimiou P, Kukar M. Lupus pernio: sarcoid-specific cutaneous manifestation associated with chronic sarcoid arthropathy. J Clin Rheumatol. 2011;17(6):343.PubMed
64.
Neville E, Mills RG, Jash DK, Mackinnon DM, Carstairs LS, James DG. Sarcoidosis of the upper respiratory tract and its association with lupus pernio. Thorax. 1976;31(6):660–4.PubMedCentralPubMed
65.
66.
Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol. 2008;9(3):155–61.PubMed
67.
Grema H, Greve B, Raulin C. Scar sarcoidosis—treatment with the Q-switched ruby laser. Lasers Surg Med. 2002;30(5):398–400.PubMed
68.
Holzmann RD, Astner S, Forschner T, Sterry G. Scar sarcoidosis in a child: case report of successful treatment with the pulsed dye laser. Dermatol Surg. 2008;34(3):393–6.PubMed
69.
House NS, Welsh JP, English JC 3rd. Sarcoidosis-induced alopecia. Dermatol Online J. 2012;18(8):4.PubMed
70.
Douri T, Chawaf AZ, Alrefaee BA. Cicatricial alopecia due to sarcoidosis. Dermatol Online J. 2003;9(1):16.PubMed
71.
Cho HR, Shah A, Hadi S. Systemic sarcoidosis presenting with alopecia of the scalp. Int J Dermatol. 2004;43(7):520–2.PubMed
72.
Sakemi H, Oiwa H. Psoriasiform plaques of sarcoidosis. Internal Med. 2009;48(5):391.
73.
Mittal RR, Singh SP, Gill SS. Psoriasiform sarcoidosis associated with depigmentation. Indian J Dermatol Venereol Leprol. 1996;62(2):103–5.
74.
Mitsuishi T, Nogita T, Kawashima M. Psoriasiform sarcoidosis with ulceration. Int J Dermatol. 1992;31(5):339–40.PubMed
75.
76.
Ichiki Y, Kitajima Y. Ulcerative sarcoidosis: case report and review of the Japanese literature. Acta Dermato-Venereol. 2008;88(5):526–8.
77.
Hunt RD, Gonzalez ME, Robinson M, Meehan SA, Franks AG Jr. Ulcerative sarcoidosis. Dermatol Online J. 2012;18(12):29.PubMed
78.
Zhang H, Ma HJ, Liu W, Yuan XY. Sarcoidosis characterized as acquired ichthyosiform erythroderma. Eur J Dermatol. 2009;19(5):516–7.
79.
Vasaghi A, Kalafi A. Unusual manifestation of cutaneous sarcoidosis: a case report of morpheaform sarcoidosis. Acta Med Iran. 2012;50(9):648–51.PubMed
80.
Kelley BP, George DE, LeLeux TM, Hsu S. Ichthyosiform sarcoidosis: a case report and review of the literature. Dermatol Online J. 2010;16(8):5.PubMed
81.
Gangopadhyay AK. Ichthyosiform sarcoidosis. Indian J Dermatol Venereol Leprol. 2001;67(2):91–2.
82.
Rampin L, Musto A, Marzola MC, Tadayyon S, Ferretti A, Chondrogiannis S, et al. Diagnosis of unknown sarcoidosis associated to erythema nodosum with 18F-FDG PET/CT. Revista Espanola de Medicina Nuclear e Imagen Mol. 2013;32(3):190–2.
83.
Ohta H, Tazawa R, Nakamura A, Kimura Y, Maemondo M, Kikuchi T, et al. Acute-onset sarcoidosis with erythema nodosum and polyarthralgia (Lofgren’s syndrome) in Japan: a case report and a review of the literature. Intern Med. 2006;45(9):659–62.PubMed
84.
O’Connor TM, Cagney D, Jahangir A, Brady A, Fitzgibbon J, Lee G, et al. Characteristics of patients presenting with erythema nodosum and sarcoidosis. Ir Med J. 2009;102(6):181–4.PubMed
85.
Donmez S, Kisacik B, Pamuk ON, Pehlivan Y, Aydogdu E, Yurekli OA, et al. Are clinical features in Lofgren’s syndrome-related erythema nodosum different from idiopathic erythema nodosum? Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):128–31.PubMed
86.
Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130(1):29–32.PubMed
87.
Pietinalho A, Ohmichi M, Hiraga Y, Lofroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(2):159–66.
88.
Judson MA. The diagnosis of sarcoidosis. Clin Chest Med. 2008;29(3):415–27, viii.
89.
Ivemark BI. Observations on the histopathology of sarcoidosis. Acta Med Scand Suppl. 1956;312:438–42.PubMed
90.
Takahashi M. Histopathology of sarcoidosis and its immunological bases. Acta Pathol Jpn. 1970;20(2):171–82.PubMed
91.
Marcoval J, Mana J, Moreno A, Gallego I, Fortuno Y, Peyri J. Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis. Arch Dermatol. 2001;137(4):427–30.PubMed
92.
Costabel U, Guzman J, Baughman RP. Systemic evaluation of a potential cutaneous sarcoidosis patient. Clin Dermatol. 2007;25(3):303–11.
93.
Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735–7.PubMed
94.
Bodaghi B, Touitou V, Fardeau C, Chapelon C, LeHoang P. Ocular sarcoidosis. Presse Med. 2012;41(6 Pt 2):e349–54.PubMed
95.
96.
Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52(4):336–46.
97.
Chapelon-Abric C. Cardiac sarcoidosis. Curr Opin Pulm Med. 2013;19(5):493–502.PubMed
98.
Martusewicz-Boros MM, Piotrowska-Kownacka D, Domagala J, Kowalewski M, Wiatr E. Cardiac sarcoidosis mimicking ischaemic infarct. Kardiol Pol. 2014;72(1):86.PubMed
99.
Nakamura S, Hashimoto Y, Nishi K, Takeda K, Mizumoto T, Demitsu T, et al. High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series. J Med Case Rep. 2014;8(1):17.PubMedCentralPubMed
100.
Rosenbach M. Practice gaps. The dermatologist’s role in sarcoidosis. JAMA Dermatol. 2013;149(6):760–1.
101.
Anolik RB, Schaffer A, Kim EJ, Rosenbach M. Thyroid dysfunction and cutaneous sarcoidosis. J Am Acad Dermatol. 2012;66(1):167–8.PubMed
102.
Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with sarcoidosis. J Am Acad Dermatol. 2011;64(4):795–6.PubMed
103.
Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R. Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):95–101.PubMed
104.
Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis—its value in present clinical practice. Ann Clin Biochem. 1989;26(Pt 1):13–8.PubMed
105.
Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168(3):323–9.PubMed
106.
Victorson DE, Choi S, Judson MA, Cella D. Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. Qual Life Res. 2014;23(4):1301–13. doi:10.​1007/​s11136-013-0567-6 (Epub 2013 Nov 9).
107.
Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550–6.PubMed
108.
Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol. 1995;131(5):617–8.PubMed
109.
Wise RD. Clinical resolution of facial cutaneous sarcoidosis with systemic colchicine and a topical corticosteroid ointment. Compr Ther. 2008 Summer;34(2):105–10.
110.
Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Dermato-Venereol. 1992;72(1):69–71.
111.
Bersani TA, Nichols CW. Intralesional triamcinolone for cutaneous palpebral sarcoidosis. Am J Ophthalmol. 1985;99(5):561–2.PubMed
112.
Callen JP. Intralesional corticosteroids. J Am Acad Dermatol. 1981;4(2):149–51.PubMed
113.
Singh SK, Singh S, Pandey SS. Cutaneous sarcoidosis without systemic involvement: response to intralesional corticosteroid. Indian J Dermatol Venereol Leprol. 1996;62(4):273–4.
114.
Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol. 2007;32(4):457–8.PubMed
115.
Gutzmer R, Volker B, Kapp A, Werfel T. [Successful topical treatment of cutaneous sarcoidosis with tacrolimus]. Hautarzt. 2003;54(12):1193–7.
116.
Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol. 2002;147(1):154–6.PubMed
117.
Vano-Galvan S, Fernandez-Guarino M, Carmona LP, Harto A, Carrillo R, Jaen P. Lichenoid type of cutaneous sarcoidosis: great response to topical tacrolimus. Eur J Dermatol. 2008;18(1):89–90.
118.
Hasegawa T, Suga Y, Mizuno Y, Haruna K, Ikeda S. Photodynamic therapy using intense pulsed light for cutaneous sarcoidosis. J Dermatol. 2012;39(6):564–5.PubMed
119.
Penrose C, Mercer SE, Shim-Chang H. Photodynamic therapy for the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2011;65(1):e12–4.PubMed
120.
Karrer S, Abels C, Wimmershoff MB, Landthaler M, Szeimies RM. Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch Dermatol. 2002;138(5):581–4.PubMed
121.
Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology. 2008;217(4):343–6.PubMed
122.
Kondo C, Watanabe D, Nakaseko H, Morishita M, Tsuboi T, Tamada Y, et al. Photodynamic therapy for recurrent sarcoid flexor tenosynovitis of the finger. J Am Acad Dermatol. 2006;55(5 Suppl):S99–101.PubMed
123.
Green JJ, Lawrence N, Heymann WR. Generalized ulcerative sarcoidosis induced by therapy with the flashlamp-pumped pulsed dye laser. Arch Dermatol. 2001;137(4):507–8.PubMed
124.
Roos S, Raulin C, Ockenfels HM, Karsai S. Successful treatment of cutaneous sarcoidosis lesions with the flashlamp pumped pulsed dye laser: a case report. Dermatol Surg. 2009;35(7):1139–40.PubMed
125.
Frederiksen LG, Jorgensen K. Sarcoidosis of the nose treated with laser surgery. Rhinology. 1996;34(4):245–6.PubMed
126.
Hocar O, Faye O, Wolkenstein P, Goldzal S, Revuz J, Cosnes A. Cutaneous sarcoidosis: efficacy of KTP laser. Ann Dermatol Venereol. 2007;134(2):174–5.PubMed
127.
James JC, Simpson CB. Treatment of laryngeal sarcoidosis with CO2 laser and mitomycin-C. Otolaryngol Head Neck Surg. 2004;130(2):262–4.PubMed
128.
Ruff T, Bellens EE. Sarcoidosis of the larynx treated with CO2 laser. J Otolaryngol. 1985;14(4):245–7.PubMed
129.
Gleeson CM, Morar N, Staveley I, Bunker CB. Treatment of cutaneous sarcoid with topical gel psoralen and ultraviolet A. Br J Dermatol. 2011;164(4):892–4.PubMed
130.
Graefe T, Konrad H, Barta U, Wollina U, Elsner P. Successful ultraviolet al treatment of cutaneous sarcoidosis. Br J Dermatol. 2001;145(2):354–5.PubMed
131.
Mahnke N, Medve-Koenigs K, Berneburg M, Ruzicka T, Neumann NJ. Cutaneous sarcoidosis treated with medium-dose UVA1. J Am Acad Dermatol. 2004;50(6):978–9.PubMed
132.
Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990;23(3 Pt 1):487–9.PubMed
133.
Marchetti M, Baker MG, Noland MM. Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases. Dermatol Online J. 2014;20(1):21250.PubMed
134.
Meyersburg D, Schon MP, Bertsch HP, Seitz CS. Uncommon cutaneous ulcerative and systemic sarcoidosis. Successful treatment with hydroxychloroquine and compression therapy. Hautarzt. 2011;62(9):691–5.PubMed
135.
Modi S, Rosen T. Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate. Cutis Cutan Med Pract. 2008;81(4):351–4.
136.
Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl. 1964;425:302–8.PubMed
137.
Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol. 1991;127(7):1034–40.PubMed
138.
Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007;56(1):69–83.PubMed
139.
Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137(1):69–73.PubMed
140.
Miyazaki E, Ando M, Fukami T, Nureki S, Eishi Y, Kumamoto T. Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect? Clin Rheumatol. 2008;27(9):1195–7.PubMed
141.
Schmitt CE, Fabi SG, Kukreja T, Feinberg JS. Hypopigmented cutaneous sarcoidosis responsive to minocycline. J Drugs Dermatol. 2012;11(3):385–9.PubMed
142.
Steen T, English JC. Oral minocycline in treatment of cutaneous sarcoidosis. JAMA Dermatol. 2013;149(6):758–60.PubMed
143.
Kircik LH. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol. 2010;9(11):1407–11.PubMed
144.
Park MK, Fontana JR, Babaali H, Gilbert-McClain LI, Stylianou M, Joo J, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121–31.
145.
Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–9.PubMed
146.
Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262–4.PubMed
147.
Veien NK. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol. 1986;4(4):75–87.
148.
Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol. 2007;25(3):334–40.
149.
Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol. 2012;8(1):95–103.PubMed
150.
Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361–83.PubMed
151.
Mosam A, Morar N. Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach. J Dermatol Treat. 2004;15(6):353–9.
152.
Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol. 1977;97(2):213–6.PubMed
153.
Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol. 2003;148(1):147–8.PubMed
154.
Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–22.PubMed
155.
Vorselaars AD, Wuyts WA, Vorselaars VM, Zanen P, Deneer VH, Veltkamp M, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–12.PubMed
156.
Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995;32(5 Pt 2):866–9.PubMed
157.
Hoch O, Muller S, Buttner G, Mensing H. [Thalidomide in the treatment of cutaneous and systemic sarcoidosis]. Hautarzt. 2001;52(10 Pt 2):962–5.
158.
Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol. 1998;39(5 Pt 2):835–8.PubMed
159.
Nguyen YT, Dupuy A, Cordoliani F, Vignon-Pennamen MD, Lebbe C, Morel P, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004;50(2):235–41.PubMed
160.
Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol. 1998;134(8):1045–6.PubMed
161.
Baughman RP, Lower EE. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol. 2004;5(6):385–94.PubMed
162.
Fazzi P, Manni E, Cristofani R, Cei G, Piazza S, Calabrese R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother. 2012;66(4):300–7.PubMed
163.
Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102(3):225–36.PubMed
164.
Dalm VA, van Hagen PM. Efficacy of lenalidomide in refractory lupus pernio. JAMA Dermatol. 2013;149(4):493–4.PubMed
165.
Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol. 2012;39(2):289–93.PubMed
166.
Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35(7):795–6.PubMed
167.
Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol. 2006;142(1):17–9.PubMed
168.
Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.PubMed
169.
Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005;53(5):917.PubMed
170.
Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis. 2012;6(6):708–12.PubMed
171.
Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141(7):910–1.PubMed
172.
Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol. 2003;2(4):413–4.PubMed
173.
Rosen T, Doherty C. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion. Dermatol Online J. 2007;13(3):14.PubMed
174.
Sene T, Juillard C, Rybojad M, Cordoliani F, Lebbe C, Morel P, et al. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. J Am Acad Dermatol. 2012;66(2):328–32.PubMed
175.
Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Aust J Dermatol. 2013. doi:10.​1111/​ajd.​12056 (Epub ahead of print).
176.
Tuchinda P, Bremmer M, Gaspari AA. A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol Ther. 2012;2(1):11.
177.
Wanat KA, Rosenbach M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch Dermatol. 2012;148(9):1097–100.PubMed
178.
Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–85.PubMed
179.
Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468–76.PubMed
180.
Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology. 2009;219(1):59–62.PubMed
181.
Fraser SJ, Hill AT, McKay DA, Reid WA, Mathers ME, MacDougall G, et al. Cutaneous tuberculosis revealed by infliximab therapy for presumed sarcoidosis. Clin Exp Dermatol. 2010;35(4):e141–2.PubMed
182.
Dhaille F, Viseux V, Caudron A, Dadban A, Tribout C, Boumier P, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology. 2010;220(3):234–7.PubMed
183.
Santos G, Sousa LE, Joao AM. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab—a paradoxical effect? A case report. An Bras Dermatol. 2013;88(6 Suppl 1):26–8.
184.
Georgiou S, Monastirli A, Pasmatzi E, Tsambaos D. Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy. Acta Dermato-Venereol. 1998;78(6):457–9.
185.
Pignone AM, Rosso AD, Fiori G, Matucci-Cerinic M, Becucci A, Tempestini A, et al. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis. J Pineal Res. 2006;41(2):95–100.PubMed
186.
York EL, Kovithavongs T, Man SF, Rebuck AS, Sproule BJ. Cyclosporine and chronic sarcoidosis. Chest. 1990;98(4):1026–9.PubMed
187.
Sahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–50.PubMed
Metadaten
Titel
A Practical Approach to Cutaneous Sarcoidosis
verfasst von
Karolyn A. Wanat
Misha Rosenbach
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2014
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-014-0079-3

Weitere Artikel der Ausgabe 4/2014

American Journal of Clinical Dermatology 4/2014 Zur Ausgabe

Review Article

Optimal Management of Skin Cancer in Immunosuppressed Patients

Review Article

A Review of Novel Therapies for Melanoma

Review Article

Follicular and Scarring Disorders in Skin of Color: Presentation and Management

Therapy in Practice

A Practical Approach to the Diagnosis, Evaluation, and Management of Cutaneous Small-Vessel Vasculitis

Short Communication

Metabolic Syndrome Prevalence in Psoriasis

Original Research Article

Impact of Functional Pruritus Compared with Mild Psoriasis on Quality of Life: A Cross-Sectional Questionnaire Study in Turkey

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

16.04.2024 | DGIM 2024 | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

12.04.2024 | Vitiligo | Nachrichten

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt
weitere anzeigen

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise